We are excited to present groundbreaking data on the application of our technology to drug discovery for intractable diseases in the fields of oncology and immunology
South San Francisco, CA (PRWEB) October 05, 2016
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in California. The presentation titled “Copying and Mining Complete Immune Systems” will take place at 9:00am Pacific time, on Friday, October 7, 2016.
“GigaGen’s approach to immunotherapy development relies on copying entire human and mouse immune repertoires and then mining them for drug candidates”, said Dr. Johnson. “Our massively parallel single cell immune repertoire technology leads the field in this area, returning results that are faster and more thorough than other technologies. We are excited to present groundbreaking data on the application of our technology to drug discovery for intractable diseases in the fields of oncology and immunology.”
The 2016 Symposium will cover topics such as the latest advances in antibody development, as well as innovative technologies that are helping to bring about the next generation of protein therapeutics and products. The meeting is designed to benefit scientists currently working in the biopharmaceutical industry who want to improve their awareness of the latest advancements in protein engineering and antibody discovery, as well as non-scientists who seek a better understanding of the processes, challenges and opportunities in the industry.
GigaGen is a biopharmaceutical company developing novel antibody and T cell therapies derived from immune repertoires. GigaGen’s technology platform captures the genetic make-up of the entire human immune repertoire, capturing and genetically analyzing B and T cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. Therapies derived from natural immune repertoires mimic the body's natural immune system - they can be more effective, can have fewer side effects, and can have faster development timelines than those developed from traditional methods. GigaGen has drug discovery projects with several pharmaceutical companies in addition to its own pipeline for development of the first recombinant intravenous immunoglobulin (IVIG) and immuno-oncology therapies. For more information visit http://www.gigagen.com.